2018. Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data. SKIN The Journal of Cutaneous Medicine. 2, (Dec. 2018), S78. DOI:https://doi.org/10.25251/skin.2.supp.78.